Obecabtagene autoleucel is a type of CAR T-cell therapy that is composed of genetically modified T-cells from the patient, which are directed against CD19.
The drug is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.